• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Vasoprotective effects of lysophosphatidic acid inhibit vascular injury caused by SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Jul 25;15(1):24622.
doi: 10.1038/s41598-025-06569-7. Vasoprotective effects of lysophosphatidic acid inhibit vascular injury caused by SARS-CoV-2 infection

Fumitaka Muramatsu[SUP] 1 2 [/SUP], Naoi Hosoe[SUP] 3 [/SUP], Tatsuya Suzuki[SUP] 4 [/SUP], Teppei Shimamura[SUP] 5 [/SUP], Yumiko Hayashi[SUP] 3 [/SUP], Kazuhiro Takara[SUP] 3 [/SUP], Lamri Lynda[SUP] 3 [/SUP], Anna Shimizu[SUP] 3 [/SUP], Weizhen Jia[SUP] 1 [/SUP], Yoshimi Noda[SUP] 1 [/SUP], Nobuyuki Takakura[SUP] 1 2 [/SUP], Toru Okamoto[SUP] 4 [/SUP], Hiroyasu Kidoya[SUP] 6 7 8 [/SUP]



Affiliations
Abstract

Vasculitis and vascular injury are induced in coronavirus disease 2019 (COVID-19) patients, suggesting an association between multi-organ failure and sequelae. Vascular endothelial dysfunction induced by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) disrupts vascular barrier function, activates coagulation pathways, and induces extravasation of inflammatory cells. In addition to employing standard anti-inflammatory and antiviral agents, using treatments that stabilize and protect blood vessels following SARS-CoV-2 infection is a potentially effective strategy to relieve COVID-19 severity. Here, we focused on the vasoprotective effects of lysophosphatidic acid (LPA), a lipid mediator with diverse activities, and investigated whether it could be a novel therapeutic for COVID-19. Three-dimensional cultures of various human vascular endothelial cells that form luminal structures showed increased expression of LPA4 and entry receptors for SARS-CoV-2 infection, mimicking blood vessels in vivo. Validation using this culture system showed that LPA attenuated SARS-CoV-2 infection-induced vascular destruction and the activation of inflammatory signaling. In experiments with infected animals, LPA administration protected blood vessels and suppressed inflammation and vascular damage in lung tissue. The activation of LPA signaling in vascular endothelial cells may be an effective therapeutic approach for mitigating vascular injury in COVID-19.

Keywords: COVID-19; Lysophosphatidic acid (LPA); SARS-CoV-2; Vascular endothelial cell; Vascular injury.

 
Back
Top Bottom